Published in Br J Haematol on June 15, 2016
Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A (2006) 3.09
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood (2010) 2.66
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem (1979) 2.54
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem (1980) 2.39
Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett (1976) 2.34
Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 2.07
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res (1976) 2.03
Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood (2013) 1.69
Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem (1998) 1.46
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood (1996) 1.39
Activation of human factor V by factor Xa and thrombin. Biochemistry (1990) 1.39
Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood (1991) 1.37
Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther (1997) 1.30
Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem (1990) 1.26
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem (1993) 1.23
Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol (2010) 1.21
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood (2007) 1.11
Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Biochemistry (2002) 1.08
Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med (1989) 1.03
Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs (2007) 1.02
A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem (2012) 1.01
Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A (2013) 1.01
Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost (2006) 1.00
Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry (1994) 0.99
Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation (2013) 0.95
Relationship between factor V and activated factor X in the generation of prothrombinase. Nature (1967) 0.92
The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J Biol Chem (2009) 0.90
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology (2004) 0.87
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am (2003) 0.85
Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. Biochem J (1997) 0.82
Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). Int J Biol Macromol (2002) 0.82
Heparin is procoagulant in the absence of antithrombin. Thromb Haemost (2008) 0.82
Structure-activity relationship of the pro- and anticoagulant effects of Fucus vesiculosus fucoidan. Thromb Haemost (2013) 0.82
The isolation of human platelet factor V. Blood (1987) 0.79
Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative. Clin Appl Thromb Hemost (2015) 0.78